Ayodola Anise is the senior director of operations for MI Health, supporting FasterCures, Public Health, Future of Aging, and Feeding Change. She brings over two decades of experience in advising on and implementing strategy, leading operations, developing staff, and collaborating for organizational effectiveness, efficiency, and equity.

Shane Liddelow is an assistant professor in the Department of Neuroscience and Physiology at the NYU Grossman School of Medicine. Liddelow’s basic research focuses on the role of non-neuronal cells in neuroinflammation that leads to neurodegeneration in diseases such as Alzheimer’s disease and ALS.

Clotilde Lagier-Tourenne is an associate professor of neurology at the Massachusetts General Institute for Neurodegeneration. Lagier-Tourenne’s lab focuses on basic science and uses a combination of genomic approaches across multiple model systems (animal models, neurons from patients, and post-mortem tissue) to identify mechanisms underlying ALS and frontotemporal dementia.

Steve Finkbeiner is director of the Center for Systems and Therapeutics and the Taube/Koret Center for Neurodegenerative Disease Research at Gladstone Institutes. Finkbeiner’s research is broadly focused across many neurodegenerative and psychiatric diseases.

Lucie Bruijn serves as the therapeutic area biomarker lead for amyotrophic lateral sclerosis (ALS) at Novartis UK.

Athena Rae Roesler is a director on the Public Health team at Milken Institute Health, where she leads a portfolio of work focused on prevention and chronic disease.

Sarah Wells Kocsis is a senior director on the public health team at Milken Institute Health, where she leads a portfolio of work focused on prevention, chronic disease, infrastructure, and other timely issues that are critical to advancing the role of public health in supporting healthy and productive communities.

Sabrina Spitaletta is a senior director on the public health team at Milken Institute Health. Spitaletta oversees operations for the mental health, prevention and chronic disease, and health equity programs. She leads the work focused on the role of employers in prioritizing whole-person health and develops stakeholder collaborations across sectors.

Madelyn McLaughlin is an associate on the public health team at the Milken Institute.

Paul is currently President, 1Rx DigiPharm Advisory, LLC and Chief Medical Officer (CMO) for Cormedix, a company harnessing taurolidine technology to combat vascular infections. He is also on the Board of Directors and CMO for Phesi, a company applying proprietary statistical platforms and web-based analytics to optimize clinical trial design and execution in oncology, neurodegenerative disease, and rare diseases.